Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.

被引：0
|
作者：
Sangro, Bruno
Galle, Peter R.
Kelley, Robin Kate
Charoentum, Chaiyut
De Toni, Enrico N.
Ostapenko, Yuriy
Heo, Jeong
Cheng, Ann-Lii
Vogel, Arndt
Marcovitz, Michelle
Abraham, Jayne
Patel, Nikunj
Negro, Alejandra
Abou-Alfa, Ghassan K.
机构：
[1] Clin Univ Navarra, Liver Unit, Pamplona, Spain
[2] Clin Univ Navarra, HPB Oncol Area, Pamplona, Spain
[3] CIBEREHD, Pamplona, Spain
[4] Univ Med Ctr, Mainz, Germany
[5] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[6] Chiang Mai Univ, Dept Internal Med, Fac Med, Maharaj Nakorn Chiang Mai Hosp, Chiang Mai, Thailand
[7] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 2, Munich, Germany
[8] LEC Reg Ctr Oncol, Kiev, Ukraine
[9] Pusan Natl Univ, Dept Internal Med, Coll Med, Busan, South Korea
[10] Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea
[11] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[12] Hannover Med Sch, Hannover, Germany
[13] AstraZeneca, Gaithersburg, MD USA
[14] IQ VIA, Patient Cent Solut, New York, NY USA
[15] Cornell Univ, Dept Med, Mem Sloan Kettering Canc Ctr, New York, NY USA
[16] Cornell Univ, Weill Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4074
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
    Sangro, Bruno
    Galle, Peter R.
    Kelley, Robin Kate
    Charoentum, Chaiyut
    De Toni, Enrico N.
    Ostapenko, Yurii
    Heo, Jeong
    Cheng, Ann-Lii
    Woods, Andrea Wilson
    Gupta, Charu
    Abraham, Jayne
    Mccoy, Carrie L.
    Patel, Nikunj
    Negro, Alejandra
    Vogel, Arndt
    Abou-Alfa, Ghassan K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23)
  • [2] Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
    Kudo, Masatoshi
    [J]. HEPATOBILIARY SURGERY AND NUTRITION, 2022, 11 (04) : 592 - 596
  • [3] Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Chan, S. L.
    Kudo, M.
    Sangro, B.
    Kelley, R. K.
    Furuse, J.
    Park, J-W.
    Sunpaweravong, P.
    Fasolo, A.
    Yau, T.
    Kawaoka, T.
    Cheng, A-L.
    Azevedo, S.
    Reig Monzon, M. E.
    Assenat, E.
    Yarchoan, M.
    He, A. R.
    Makowsky, M.
    Gupta, C.
    Negro, A.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1456 - S1456
  • [4] Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Chan, S. L.
    Kudo, M.
    Sangro, B.
    Kelley, R. K.
    Furuse, J.
    Park, J-W.
    Sunpaweravong, P.
    Fasolo, A.
    Yau, T.
    Kawaoka, T.
    Cheng, A-L.
    Azevedo, S.
    Reig Monzon, M. E.
    Assenat, E.
    Yarchoan, M.
    He, A. R.
    Makowsky, M.
    Gupta, C.
    Negro, A.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1456 - S1456
  • [5] Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study
    Vogel, A.
    Chan, S.
    Furuse, J.
    Tak, W.
    Masi, G.
    Varela, M.
    Kim, J.
    Tanasanvimon, S.
    Reig, M.
    Dayyani, F.
    Makowsky, M.
    Marcovitz, M.
    Negro, A.
    Abou-Alfa, G.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S380 - S381
  • [6] OUTCOMES BY BASELINE LIVER FUNCTION IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA TREATED WITH TREMELIMUMAB AND DURVALUMAB IN THE PHASE 3 HIMALAYA STUDY
    Vogel, Arndt
    Chan, Stephen L.
    Furuse, Junji
    Tak, Won Young
    Masi, Gianluca
    Varela, Maria
    Kim, Jee Hyun
    Tanasanvimon, Suebpong
    Reig, Maria
    Dayyani, Farshid
    Makowsky, Mallory
    Marcovitz, Michelle
    Negro, Alejandra
    Abou-Alfa, Ghassan K.
    [J]. HEPATOLOGY, 2022, 76 : S1418 - S1419
  • [7] FOUR-YEAR OVERALL SURVIVAL UPDATE FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Abou-Alfa, Ghassan K.
    Chan, Stephen Lam
    Kelley, Kate
    Lau, George
    Kudo, Masatoshi
    Sukeepaisarnjaroen, Wattana
    De Toni, Enrico N.
    Furuse, Junji
    Kang, Yoon Koo
    Galle, Peter R.
    Rimassa, Lorenza
    Heurgue, Alexandra
    Tam, Vincent C.
    Tu Van Dao
    Thungappa, Satheesh Chiradoni
    Breder, Valeriy
    Ostapenko, Yuriy
    Reig, Maria
    Makowsky, Mallory
    Gupta, Charu
    Negro, Alejandra
    Sangro, Bruno
    [J]. HEPATOLOGY, 2023, 78 : S90 - S91
  • [8] Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Sangro, B.
    Chan, S.
    Kelley, R.
    Lau, G.
    Kudo, M.
    Sukeepaisarnjaroen, W.
    De Toni, E.
    Furuse, J.
    Kang, Y.
    Galle, P.
    Rimassa, L.
    Heurgue, A.
    Tam, V.
    Dao, T.
    Thungappa, S.
    Breder, V.
    Ostapenko, Y.
    Reig, M.
    Makowsky, M.
    Gupta, C.
    Negro, A.
    Abou-Alfa, G.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S168 - S168
  • [9] Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Sangro, B.
    Chan, S. L.
    Kelley, R. K.
    Lau, G.
    Kudo, M.
    Sukeepaisarnjaroen, W.
    Yarchoan, M.
    De Toni, E. N.
    Furuse, J.
    Kang, Y. K.
    Galle, P. R.
    Rimassa, L.
    Heurgue, A.
    Tam, V. C.
    Van Dao, T.
    Thungappa, S. C.
    Breder, V.
    Ostapenko, Y.
    Reig, M.
    Makowsky, M.
    Paskow, M. J.
    Gupta, C.
    Kurland, J. F.
    Negro, A.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 (05) : 448 - 457
  • [10] Outcomes by comorbidities (CMs) with tremelimumab (T) and durvalumab (D) in the phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
    Rimassa, L.
    Dayyani, F.
    Kelley, R. K.
    Sangro, B.
    Chan, S. L.
    Mccoy, C. L.
    Paskow, M. J.
    Makowsky, M.
    Gupta, C.
    Ran, D.
    Negro, A.
    Abou-Alfa, G. K.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S77 - S78
12345